Related Experiment Video
Updated: Jan 10, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction-Associated
Jing Zhao1,2,3, Ferenc E Mózes4, Xin-Yu Xu1,2,3
1Urologic Nephrology Center Jiangnan University Medical Center Wuxi China.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease globally. Previous studies have shown that MASLD is an independent risk factor for chronic kidney disease (CKD), but the variations in estimated glomerular filtration rate (eGFR) levels across countries with different ethnic backgrounds have not been extensively reported. We enrolled 3308 participants with biopsy-proven MASLD from 34 centers in this multinational study and analyzed the associations between eGFR and histological severity of liver fibrosis in different countries. European participants had lower eGFR levels (92.2 ± 20.7 vs. 104.7 ± 17.3 mL/min/1.73 m2) and significant liver fibrosis (61.4 vs. 32.4%) than Asian individuals. In Asia, Chinese participants had the highest mean eGFR level at 105.8 mL/min/1.73 m2, while Malaysian participants had the lowest at 87.3 mL/min/1.73 m2 (p < 0.001). In Europe, French participants had the highest mean eGFR level at 95.3 mL/min/1.73 m2, while Romanian individuals had the lowest at 81.1 mL/min/1.73 m2 (p < 0.001). eGFR levels were inversely associated with liver fibrosis in Asian individuals (OR: 0.793, 95%CI: 0.685-0.917, p = 0.002), even after adjusting for traditional renal risk factors, but not in Europeans. Our findings provide the basis for further investigation of the burden of MASLD on CKD risk in different countries.
Insights
Metabolic dysfunction-associated steatotic liver disease (MASLD) impacts kidney function differently across ethnicities. European MASLD patients show lower eGFR and more fibrosis than Asian patients, with varying eGFR levels within continents.
Area of Science:
- Hepatology and Nephrology
- Global Health
- Metabolic Diseases
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern.
- MASLD is recognized as an independent risk factor for chronic kidney disease (CKD).
- Ethnic variations in estimated glomerular filtration rate (eGFR) among MASLD patients are not well-documented.
Purpose of the Study:
- To investigate the association between eGFR and liver fibrosis severity in a multinational cohort of MASLD patients.
- To explore ethnic and geographic variations in eGFR levels and their relationship with MASLD histological features.
Main Methods:
- A multinational study involving 3308 participants with biopsy-proven MASLD from 34 centers.
- Analysis of eGFR levels and liver fibrosis severity across different countries and ethnic groups.
- Statistical analysis to determine associations between eGFR, fibrosis, and traditional renal risk factors.
Main Results:
- European MASLD participants exhibited lower mean eGFR (92.2 mL/min/1.73 m²) and higher rates of significant liver fibrosis (61.4%) compared to Asian participants.
- Significant variations in mean eGFR were observed within continents: Chinese (105.8 mL/min/1.73 m²) and Malaysian (87.3 mL/min/1.73 m²) in Asia; French (95.3 mL/min/1.73 m²) and Romanian (81.1 mL/min/1.73 m²) in Europe.
- eGFR was inversely associated with liver fibrosis in Asian individuals (OR: 0.793) after adjusting for risk factors, but this association was not found in Europeans.
Conclusions:
- Ethnic background and geographic location significantly influence eGFR levels and the relationship between MASLD and CKD risk.
- The inverse association between eGFR and liver fibrosis in MASLD is present in Asian populations but not in European populations.
- Further research is warranted to understand the global burden of MASLD on CKD and to tailor clinical management strategies based on ethnic and geographic factors.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...